PD-1/PD-L1 inhibitors for immuno-oncology: from antibodies to small molecules
Q Geng, P Jiao, P Jin, G Su, J Dong… - Current Pharmaceutical …, 2017 - ingentaconnect.com
Background: The recent regulatory approvals of immune checkpoint protein inhibitors, such
as ipilimumab, pembrolizumab, nivolumab, atezolizumab, durvalumab, and avelumab …
as ipilimumab, pembrolizumab, nivolumab, atezolizumab, durvalumab, and avelumab …
PD-1/PD-L1 Inhibitors for Immuno-oncology: From Antibodies to Small Molecules.
Q Geng, P Jiao, P Jin, G Su, J Dong… - Current Pharmaceutical …, 2018 - europepmc.org
Background The recent regulatory approvals of immune checkpoint protein inhibitors, such
as ipilimumab, pembrolizumab, nivolumab, atezolizumab, durvalumab, and avelumab …
as ipilimumab, pembrolizumab, nivolumab, atezolizumab, durvalumab, and avelumab …
[引用][C] PD-1/PD-L1 Inhibitors for Immuno-oncology: From Antibodies to Small Molecules
Q Geng, P Jiao, P Jin, G Su, J Dong, B Yan - Current Pharmaceutical …, 2018 - cir.nii.ac.jp
PD-1/PD-L1 Inhibitors for Immuno-oncology: From Antibodies to Small Molecules | CiNii
Research CiNii 国立情報学研究所 学術情報ナビゲータ[サイニィ] 詳細へ移動 検索フォームへ移動 …
Research CiNii 国立情報学研究所 学術情報ナビゲータ[サイニィ] 詳細へ移動 検索フォームへ移動 …
PD-1/PD-L1 Inhibitors for Immuno-oncology: From Antibodies to Small Molecules
Q Geng, P Jiao, P Jin, G Su… - Current …, 2018 - pubmed.ncbi.nlm.nih.gov
Background The recent regulatory approvals of immune checkpoint protein inhibitors, such
as ipilimumab, pembrolizumab, nivolumab, atezolizumab, durvalumab, and avelumab …
as ipilimumab, pembrolizumab, nivolumab, atezolizumab, durvalumab, and avelumab …